AFFILIATIONS
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
5 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
6 Fred Hutch Center For Community Health Promotion, Sunnyside, Washington, United States
7 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
8 King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
9 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States
10 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
11 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
12 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
13 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
ABSTRACT
Background:
Hypogammaglobulinemia and infections are common following CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy. Intravenous immunoglobulin (IVIG) is frequently administered as supportive care, but registry-based data describing patient selection and outcomes following IVIG administration remain limited.
Methods:
We performed a retrospective registry-based analysis of 3,204 patients undergoing commercial CD19 CAR-T therapy using publicly available dataset P-6093 from the Center for International Blood and Marrow Transplant Research (CIBMTR). Overall survival (OS) was evaluated using multivariable Cox regression, and infection-related mortality (IRM) was evaluated using Fine–Gray competing-risk regression. Sensitivity analyses included inverse probability of treatment weighting (IPTW), landmark analyses beginning 30, 60, and 90 days after CAR-T infusion, time-dependent Cox modeling to evaluate potential immortal time bias, proportional hazards testing using Schoenfeld residuals, simplified Fine–Gray models for sparse events, and complete-case analyses.
Results:
Among 3,204 patients, 861 (26.9%) received IVIG and 2,343 (73.1%) did not. Mean age was 60 years in both groups. IVIG recipients more frequently had prior hematopoietic cell transplantation (36% vs 22%), higher HCT-CI scores (≥5: 14% vs 6.9%), axicabtagene ciloleucel (89% vs 82%), ≥4 prior lines of therapy (41% vs 35%), grade ≥3 CRS (8.7% vs 6.7%), grade ≥3 ICANS (24% vs 18%), corticosteroid exposure (52% vs 41%), and tocilizumab exposure (61% vs 52%). Documented infections were also more common among IVIG recipients (any infection 29% vs 20%; viral 15% vs 8.4%; bacterial 19% vs 12%). Overall mortality was lower in the IVIG group (37% vs 45%), and infection-related mortality was 0.7% versus 1.5%. Despite higher baseline risk and infectious burden, IVIG administration was associated with improved OS in multivariable Cox regression (HR 0.64, 95% CI 0.55–0.75; P<0.001) and IPTW-adjusted Cox regression (HR 0.62, 95% CI 0.53–0.73; P<0.001). IVIG was associated with a lower point estimate for IRM in Fine–Gray regression (SHR 0.35, 95% CI 0.10–1.22; P=0.099; simplified model SHR 0.33, 95% CI 0.10–1.14; P=0.079). Landmark analyses at 30 days (HR 0.67), 60 days (HR 0.72), and 90 days (HR 0.73) after infusion remained significant (all P<0.001). Findings were consistent across complete-case and time-dependent Cox sensitivity analyses.
Conclusions:
IVIG administration after commercial CD19 CAR-T therapy was more common among patients with documented infections and higher-risk clinical features, yet remained associated with significantly improved overall survival across multiple sensitivity analyses. IVIG was also associated with a lower point estimate for infection-related mortality. These findings support prospective evaluation of IVIG strategies for infection-risk mitigation after CAR-T therapy.